Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.

Taylor PC, Schiff MH, Wang Q, Jiang Y, Zhuang Y, Kurrasch R, Daga S, Rao R, Tak PP, Hsu B.

Ann Rheum Dis. 2018 May;77(5):658-666. doi: 10.1136/annrheumdis-2017-212496. Epub 2018 Feb 26.

PMID:
29483080
2.

Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.

Schiff MH, Sadowski P.

Rheumatol Int. 2017 Feb;37(2):213-218. doi: 10.1007/s00296-016-3621-1. Epub 2016 Dec 23.

PMID:
28012023
3.

Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.

Müller RB, von Kempis J, Haile SR, Schiff MH.

Semin Arthritis Rheum. 2015 Aug;45(1):28-34. doi: 10.1016/j.semarthrit.2015.02.009. Epub 2015 Mar 3.

PMID:
25895697
4.
5.

Response to: 'is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?' by Fleishman and Yazici.

Schiff MH, Jaffe JS, Freundlich B.

Ann Rheum Dis. 2014 Sep;73(9):e55. doi: 10.1136/annrheumdis-2014-205938. Epub 2014 Jun 24. No abstract available.

PMID:
24962874
6.

Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al.

Schiff MH.

Arthritis Care Res (Hoboken). 2013 Nov;65(11):1892. No abstract available.

PMID:
24892177
8.

Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al.

Schiff MH.

Arthritis Care Res (Hoboken). 2013 Nov;65(11):1892. doi: 10.1002/acr.22076. No abstract available.

9.

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.

van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijtens K, Furst DE.

J Rheumatol. 2012 Jul;39(7):1326-33. doi: 10.3899/jrheum.111171. Epub 2012 May 15.

PMID:
22589265
10.

Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.

Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS.

Am J Gastroenterol. 2012 Mar;107(3):379-86. doi: 10.1038/ajg.2011.443. Epub 2011 Dec 20.

11.

Integrated safety in tocilizumab clinical trials.

Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF.

Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455. Epub 2011 Sep 1.

12.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
13.
14.

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.

Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B.

J Rheumatol. 2011 Jun;38(6):990-6. doi: 10.3899/jrheum.100935. Epub 2011 Mar 1.

15.

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.

Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC.

Arthritis Care Res (Hoboken). 2011 Mar;63(3):373-82. doi: 10.1002/acr.20372. Epub 2010 Oct 18.

16.

Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries.

Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, McCroskery P, Baumgartner SW, Markenson JA.

J Rheumatol. 2011 Jan;38(1):21-8. doi: 10.3899/jrheum.100347. Epub 2010 Oct 15.

PMID:
20952478
17.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19995740
18.

Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial.

Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, Kavanaugh A, Molitor JA, Schiff MH, Posever JO, Bathon JM, Kivitz AJ, Samodal R, Belardi F, Dennehey C, van den Broek T, van Wijk F, Zhang X, Zieseniss P, Le T, Prakken BA, Cutter GC, Albani S.

Arthritis Rheum. 2009 Nov;60(11):3207-16. doi: 10.1002/art.24916.

19.

Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.

Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, Simon LS, Weaver AL.

J Rheumatol Suppl. 2008 Feb;81:4-30; quiz 31-4. Review.

PMID:
19193621
20.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. No abstract available. Erratum in: Ann Rheum Dis. 2009 Mar;68(3):452. Kavanaugh, A [added].

PMID:
19022808
21.

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.

van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr; ATLAS Study Group.

Ann Rheum Dis. 2009 Jun;68(6):922-9. doi: 10.1136/ard.2007.087270. Epub 2008 Aug 13.

22.
23.

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.

van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, Davis JC Jr, Wong RL, Kupper H, Collantes E; ATLAS Study Group.

Ann Rheum Dis. 2008 Sep;67(9):1218-21. Epub 2007 Dec 4.

24.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME.

Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii2-22. Review. No abstract available. Erratum in: Ann Rheum Dis. 2008 Feb;67(2):280.

25.

A retrospective analysis of low-field strength magnetic resonance imaging and the management of patients with rheumatoid arthritis.

Schiff MH, Hobbs KF, Gensler T, Keenan GF.

Curr Med Res Opin. 2007 May;23(5):961-8.

PMID:
17519063
26.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, Keystone EC, Schiff MH, van Riel PL, Weinblatt ME, Weisman MH.

Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii2-15. No abstract available.

27.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr; ATLAS Study Group.

Arthritis Rheum. 2006 Jul;54(7):2136-46.

28.

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.

Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW.

J Rheumatol. 2006 May;33(5):854-61. Epub 2006 Mar 15.

PMID:
16541481
29.

Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM.

Drugs Aging. 2006;23(2):167-78.

PMID:
16536638
30.

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.

Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME.

J Rheumatol. 2006 Apr;33(4):659-64. Epub 2006 Feb 15.

PMID:
16482646
31.

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.

Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C.

Ann Rheum Dis. 2006 Jul;65(7):889-94. Epub 2006 Jan 26.

32.

Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B.

Ann Rheum Dis. 2006 Aug;65(8):1006-12. Epub 2006 Jan 5.

33.

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.

Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA; RADIUS Investigators.

Curr Med Res Opin. 2006 Jan;22(1):185-98.

PMID:
16393444
34.

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.

Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.

Curr Med Res Opin. 2006 Jan;22(1):169-83.

PMID:
16393443
35.
36.
37.

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.

Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.

Arthritis Rheum. 2004 Sep;50(9):2858-68.

38.

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.

Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB.

J Rheumatol. 2004 Aug;31(8):1532-7.

PMID:
15290731
39.

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.

Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, Liu T, Solinger AM.

Arthritis Rheum. 2004 Jun;50(6):1752-60.

40.

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.

Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, Cohen SB, Gangnon RE, Schiff MH.

J Rheumatol. 2004 Jun;31(6):1098-102.

PMID:
15170921
41.
42.
43.

Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis.

Schiff MH, Strand V, Oed C, Loew-Friedrich I.

Drugs Today (Barc). 2000 Jun;36(6):383-94.

PMID:
12861359
44.

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results.

Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, Martin RW, Spencer-Green GT.

J Rheumatol. 2003 Apr;30(4):691-6.

PMID:
12672185
45.

A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P.

Rheumatology (Oxford). 2003 Feb;42(2):244-57.

PMID:
12595618
46.

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK.

Arthritis Rheum. 2002 Jun;46(6):1443-50.

47.

Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide.

Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS.

Ann Rheum Dis. 2002 Apr;61(4):290-7. Review.

48.

Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.

Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, Weinblatt M, Taborn J, Weaver A, Burge DJ, Schiff MH.

J Rheumatol. 2001 Jun;28(6):1238-44.

PMID:
11409115
49.

Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.

Schiff MH, Whelton A.

Semin Arthritis Rheum. 2000 Dec;30(3):196-208. Review.

PMID:
11124283
50.

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK.

N Engl J Med. 2000 Nov 30;343(22):1586-93. Erratum in: N Engl J Med 2001 Jan 18;344(3):240. N Engl J Med 2001 Jan 4;344(1):76.

Supplemental Content

Loading ...
Support Center